4 hybrid o bell, Design swyddi yn Paddington
Hyderus o ran Anabledd
Gweithio o bell
Lleoliad
- UK
- London
- West London
- Paddington (4)
Dyddiad hysbysebu
Categori
Math o gytundeb
Oriau
- Llawn amser (4)
Mewngofnodwch nawr i greu rhybudd e-bost a derbyn y swyddi diweddaraf ar gyfer y chwiliad hon yn syth i'ch e-bost
MewngofnodiSAP S/4 HANA Functional Consultant - Finance
- 20 June 2024
- Hays Specialist Recruitment - London, London, W2 6BD
- £700.0 to £800.0 per day
- £700 per day umbrella
- Hybrid o bell
- Cytundeb
- Llawn amser
A SAP S/4 HANA Functional Consultant is needed to support a leading technology-communication provider. Are you ready for your next professional adventure? Your new role We have an opportunity for a SAP S/4 HANA Functional Consultant to join our client's team ...
DMPK Lead - growing biotech
- 24 May 2024
- Hays Specialist Recruitment - London / remote, London, W2 1HQ
- £80,000.0 to £115,000.0 per year
- £80-115,000 plus package
- Hybrid o bell
- Parhaol
- Llawn amser
Your new company Hays Life Sciences have been exclusively retained by a VC backed biotech that has already raised tens of millions of pounds of funding and is using its novel platform technology to develop innovative medicines for areas of unmet need, allowing...
Principal / Lead Computational Biologist - NLP
- 03 June 2024
- Hays Specialist Recruitment - London, London, W2 1HQ
- £70,000.0 to £105,000.0 per year
- £70-105,000 plus package
- Hybrid o bell
- Parhaol
- Llawn amser
Your new company You will be joining a highly innovative biotech in London developing novel drugs across a range of disease areas as they go into their next phase of growth. This company has a proprietary platform that integrates a range of algorithms and ...
Principal Computational Chemist - drug discovery
- 03 June 2024
- Hays Specialist Recruitment - London / hybrid, London, W2 1HQ
- £65,000.0 to £100,000.0 per year
- £65-100,000 plus bonus and package
- Hybrid o bell
- Parhaol
- Llawn amser
Your new company You'll be joining a VC backed biotech that has already raised tens of millions of pounds of funding and is using its novel platform technology to develop innovative medicines for areas of unmet need, allowing you to have a significant impact ...
- 1